Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

TreeHouse Foods Faces Slowdown as Shoppers Cut Back on Even Cheaper Groceries

by Team Lumida
March 5, 2025
in Health and Longevity
Reading Time: 4 mins read
A A
0
high-angle photography of grocery display gondola

Photo by Peter Bond on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  • TreeHouse Foods, a major supplier of private-label goods for retailers like Walmart and Target, is experiencing slower sales growth as inflation-weary consumers reduce spending on lower-cost groceries.
  • The company is focusing on cost-cutting measures, including supply-chain efficiencies and product adjustments, to protect margins in a challenging demand environment.
  • TreeHouse is expanding selectively through acquisitions while exiting less profitable product lines to streamline operations.
  • Analysts emphasize the need for operational improvements after recent production issues and recalls.

What Happened?

TreeHouse Foods, a leading manufacturer of private-label products for major retailers, is seeing a slowdown in sales growth as inflation-strained consumers cut back on even lower-cost grocery items. While private-label goods gained popularity during the pandemic and inflationary periods, demand has softened recently, with unit sales in key categories growing just 0.6% in late 2024 compared to 4.5% growth earlier in the year. In response, TreeHouse is implementing cost-saving measures, such as automating production processes and renegotiating supplier contracts, to reduce supply-chain costs by $250 million by 2027. The company is also refining its product portfolio, exiting less profitable areas like ready-to-drink beverages while expanding in others, including coffee and tea, through strategic acquisitions.


Why It Matters?

The slowdown in private-label sales reflects broader consumer behavior shifts as inflation continues to pressure household budgets. For investors, this signals potential headwinds for companies reliant on discretionary spending, even in traditionally resilient sectors like groceries. TreeHouse’s focus on cost control and profitability over aggressive sales growth highlights the challenges of navigating a softer demand environment. Additionally, operational missteps, such as production delays and product recalls, have weighed on the company’s performance, underscoring the importance of execution in maintaining investor confidence.


What’s Next?

TreeHouse plans to continue its cost-cutting initiatives while selectively expanding into high-growth areas like coffee and tea. The company’s ability to streamline operations and avoid further production issues will be critical to stabilizing its performance. Analysts expect slower growth in the near term, with TreeHouse forecasting a 3.5% decline in adjusted net sales for the first quarter of 2025. Investors should monitor the company’s progress in improving operational efficiency, managing its product portfolio, and adapting to evolving consumer spending patterns.

Source
Previous Post

China Strikes Back: Tariffs and Export Controls Escalate U.S.-China Trade War

Next Post

$2 Billion Loan Fuels Massive AI Data Center in Utah Amid Surging Demand

Recommended For You

VO₂ Max Is the Longevity Fitness Metric Most People Ignore

by Team Lumida
1 day ago
a woman wearing a mask and running in a field

Key Takeaways Powered by lumidawealth.com VO₂ max is one of the strongest measurable predictors of longevity and all-cause mortality. Higher VO₂ max reflects better heart, lung, and mitochondrial function...

Read more

Melatonin Is the Sleep Timing Hack — Not a Knockout Pill

by Team Lumida
3 days ago
Melatonin Is the Sleep Timing Hack — Not a Knockout Pill

Key Takeaways Powered by lumidawealth.com Melatonin works best as a circadian “time cue” (sleep schedule/jet lag), not as a general sedative for chronic insomnia. Timing matters more than dose:...

Read more

Sleep Regularity Is the Longevity Hack

by Team Lumida
3 days ago
woman sleeping on bed under blankets

Key Takeaways: Powered by lumidawealth.com Sleep regularity often matters more than total sleep duration for long-term health outcomes. Irregular sleep schedules are linked to higher risks of metabolic disease,...

Read more

Morning Sunlight: The Low-Effort Longevity Habit That Resets Your Biology

by Team Lumida
6 days ago
sun setting over the mountains

Key Takeaways: Powered by lumidawealth.com 5–15 minutes of morning sunlight exposure helps anchor your circadian clock and improve nighttime sleep. Better circadian alignment is linked to improved metabolism, hormone...

Read more

Protein Timing: The Longevity Hack You Didn’t Know You Needed

by Team Lumida
1 week ago
a container of protein powder next to a spoon

Key Takeaways: Powered by lumidawealth.com Protein intake, especially when spread throughout the day, supports muscle maintenance and longevity. Consuming protein-rich meals in the morning and after workouts maximizes muscle...

Read more

Alzheimer’s Diagnosis Is Fracturing—And Patients Are Caught in the Middle

by Team Lumida
1 week ago
doctor holding red stethoscope

Key takeaways Powered by lumidawealth.com Competing diagnostic standards are leading to contradictory Alzheimer’s diagnoses for the same patient. One camp defines Alzheimer’s biologically by amyloid presence, while another requires...

Read more

AI Is Moving From “Wellness Hype” to Healthcare Infrastructure

by Team Lumida
1 week ago
man running on road near grass field

Key takeaways Powered by lumidawealth.com AI is compressing the cost and time of diagnosis, monitoring, and clinical decision support—pushing healthcare toward earlier intervention and prevention. The biggest near-term value...

Read more

Diet Is the Biggest Longevity Lever Most People Underuse

by Team Lumida
2 weeks ago
poached egg with vegetables and tomatoes on blue plate

Key takeaways The NHS “Eatwell” approach emphasizes variety + proportions across 5 food groups, plus hydration, to support healthy weight and overall health. Most people (UK context) are...

Read more

Longevity Becomes the Next Mega-Market as Healthcare Shifts From Treating Disease to Extending Healthspan

by Team Lumida
2 weeks ago
diagram

Key takeaways Longevity is shifting healthcare from reactive treatment to proactive health optimization, expanding lifetime spending per person. Breakthroughs in metabolic drugs, early diagnostics, AI-driven prevention, and precision...

Read more

Ozempic Turns Weight Loss Into a New “Infrastructure” Market for Healthcare—and Investors

by Team Lumida
2 weeks ago
Ozempic Turns Weight Loss Into a New “Infrastructure” Market for Healthcare—and Investors

Key takeaways What it is: Ozempic is a once-weekly GLP-1 medicine approved for type 2 diabetes and to reduce major cardiovascular risk in certain adults with type 2...

Read more
Next Post
blue UTP cord

$2 Billion Loan Fuels Massive AI Data Center in Utah Amid Surging Demand

gold and black metal tool

Gold Surges as Trade War Escalation Drives Demand for Safe-Haven Assets

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

GSK to Receive $370 Million From U.S. Patent Litigation Settlement Over mRNA Covid-19 Vaccines

GSK to Receive $370 Million From U.S. Patent Litigation Settlement Over mRNA Covid-19 Vaccines

August 8, 2025
President Donald Trump

Trump’s Bold Promise: Bitcoin to Dominate America’s Future!

July 28, 2024
Amphenol Nears $10.5 Billion Deal for CommScope’s Broadband Unit Amid AI Data Center Boom

Amphenol Nears $10.5 Billion Deal for CommScope’s Broadband Unit Amid AI Data Center Boom

August 4, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018